Bristol-Myers Squibb Company (NYSE:BMY) has tumbled 2.73% during the past week and has dropped 0.14% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.56%. Bristol-Myers Squibb Company (NYSE:BMY) has underperformed the index by 1.05% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $72.00 on Friday but the bulls could not build on the opening and the stock topped out at $72.00 for the day. The stock traded down to $70.13 during the day, due to lack of any buying support eventually closed down at $70.67 with a loss of -1.48% for the day. The stock had closed at $71.73 on the previous day. The total traded volume was 15,007,684 shares.
The company shares have rallied 5.79% from its 1 Year high price. On Jun 6, 2016, the shares registered one year high at $75.12 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $71.78 and the 200 Day Moving Average price is recorded at $66.92.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Elicker John E, officer (SVP, Public Affairs & IR) of Bristol Myers Squibb Co, had unloaded 11,820 shares at an average price of $72.69 in a transaction dated on June 14, 2016. The total value of the transaction was worth $859,196.
Many analysts have stated their opinion on the company shares. Jefferies maintains its rating on Bristol-Myers Squibb Company (NYSE:BMY). The global brokerage major raises the current price target from $76 per share to $78 per share. Analysts at the Jefferies have a current rating of Hold on the shares. The rating by the firm was issued on June 14, 2016. Currently the company Insiders own 0.24% of Bristol-Myers Squibb Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -15.67% . Institutional Investors own 74.66% of Bristol-Myers Squibb Company shares. During last six month period, the net percent change held by insiders has seen a change of -0.7%.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.